Ibrutinib versus bendamustine plus rituximab for first-line treatment of 65 or older patients with untreated chronic lymphocytic leukemia without del(17p)/TP53 mutation in China: a lifetime economic research study

Ibrutinib versus bendamustine plus rituximab for first-line treatment of 65 or older patients with untreated chronic lymphocytic leukemia without del(17p)/TP53 mutation in China: a lifetime economic research study

Abstract Background The incidence and mortality rates of patients with chronic lymphocytic leukemia (CLL) in China have recently increased. This study performed a long-term economic evaluation of the first-line treatment strategies ibrutinib (IB) or bendamustine (BE) plus rituximab (RI) for previous...

Full description

Bibliographic Details
Main Authors: Yuan Hong, Xichuang Chen, Yuanquan Hong, Xingfang Xiao, Yan Wang, Xiaohong You, Jingyi Mi, Tao Zhou, Panpan Zheng, Zhihu Huang
Format: Article
Language:English
Published: BMC 2023-12-01
Series:BMC Health Services Research
Subjects:
Chronic lymphocytic leukemia
Cost effectiveness
Ibrutinib
Bendamustine
Rituximab
Quality adjusted life-year
Online Access:https://doi.org/10.1186/s12913-023-10402-0

Internet

https://doi.org/10.1186/s12913-023-10402-0

Similar Items